Navigation Links
First live targeting of tumors with RNA-based technology
Date:11/30/2009

DURHAM, N.C. Finding and treating a tumor without disturbing normal tissue presents challenges sometimes the most effective therapies can be invasive and harsh.

Researchers at Duke University Medical Center have devised a way they might deliver the right therapy directly to tumors using special molecules, called aptamers, which specifically bind to living tumor tissue.

They screened a large pool of aptamers in a rodent with liver cancer until they found the best molecule to bind to a tumor protein.

"We are already exploring attaching chemicals to the aptamers, so the aptamer molecules could deliver tumor-killing agents where they are needed, which is the next phase of our research," said senior author Bryan Clary, M.D., chief of the Division of Hepatopancreatobiliary and Oncologic Surgery.

The study was published in Nature Chemical Biology online on Nov. 29.

Aptamers are small pieces of RNA that bind to a specific target molecule, usually a protein. They offer ease of use because they can be easily regenerated and modified and therefore have increased stability over some other agents, such as protein-based antibodies. Notably, they have a very low chance of immune-system interference, making them great candidates for tumor diagnosis and therapy.

"Most importantly, it's not necessary to have detailed knowledge of protein changes in the disease before the selection process," said lead author Jing Mi, M.D., Ph.D., assistant professor in the Duke Department of Surgery. "This greatly simplifies the process of molecular probe development. The selected aptamers can be used to discover proteins not previously linked with the disease in question, which could speed up the search for effective therapies."

The researchers used a large pool of RNA strands and applied them to a rodent with a liver tumor, the type of metastatic tumor that often results from a colon cancer tumor.

"We hypothesized that the RNA molecules that bind to normal cellular elements would be filtered out, and this happened," said Clary, who treats colon cancer patients. "In this way, we found the RNA molecules that went specifically to the tumor."

The researchers removed the tumor, extracted the specific RNA in the tumor, amplified these pieces of RNA to create a greater amount, and reinjected the molecules to learn which bound most tightly to the tumor. They repeated this process 14 times to find a good candidate.

The team found a tumor-targeting RNA aptamer that specifically bound to RNA helicase p68, a nuclear protein produced in colorectal tumors.

"This aptamer not only binds to p68 protein in cell culture, but also preferentially binds to cancer deposits in a living animal," Mi said. "The nice thing about this aptamer approach is that it could be used to discover the molecular signatures of many other diseases."

Clary said the process could be repeated with different types of tumors. For example, a scientist might take a breast cancer line and grow it in the lung as a metastasis model and then perform in vivo selection to identify RNAs specifically binding to the lung tumor.

"This would work, theoretically," Clary said. "The idea of selecting molecules targeting a tumor growing in a body that results in a useful reagent for biologic exploration and therapy delivery in tumors is exciting."

In fact, based on earlier research done with proteins called peptides, the researchers expected that the aptamer process would find proteins in the blood vessels feeding the liver tumor, but instead they found the p68 target inside of tumor cells. "We think this is a valuable target because delivering to the sites inside of cells may make it easier to treat an entire tumor with drugs that are 'escorted' by the aptamer," Clary said.

He said that repeating the selection and amplification process with the same liver tumor could lead to development of other aptamers that bind well to proteins in tumor tissue besides p68. The team focused its initial efforts on developing an escort for p68 because this protein was known to be overexpressed in colon cancer.


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. ShowMyPC Provides First Online Service in the World to Access Personal Computers from Anywhere Using Microsoft Remote Desktop
2. Simbionix First Procedure Rehearsal Studio(TM) Training Workshop
3. First Time-Door is Open for Family Discussion of Bipolar Disorder
4. Implant-based cancer vaccine is first to eliminate tumors in mice
5. Vanderbilt scientists report first effective medical therapy for rare stomach disorder
6. Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice
7. MinuteClinic Opens First Retail Clinic in Washington, D.C. at CVS/pharmacy Store in Northeast
8. First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM)
9. Nordic Naturals Ultimate Omega(TM) First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program
10. Pivotal study for PSD502 -- the first potential treatment for premature ejaculation
11. Diet Delivery Company Bistro MD Is Giving Away $1,500 in First Ever Creative Writing Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Cirrus Medical Staffing, ... new website, http://www.cirrusmedicalstaffing.com . The new site pairs a robust job search ... professionals who are traveling on short-term assignments to healthcare facilities around the country. ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... Golden Bridge Awards® - for Risk Management Solution Innovations and Security Solution for ... online platform released in 2017 and its DHS SAFETY Act-designated enterprise security assessment ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... collection of unique masks and serums that perfectly fuse the beauty of naturally ... at the 2017 Indie Beauty Expo on August 23rd & 24th in New ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western North Carolina’s ... a popular international aesthetics conference for medical professionals about the positive impact ... and his growing practice. , Dr. George K. Ibrahim shared the ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology: